Dave & Buster’s

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Netmarble Corporation bets on staged rollout to de-risk The Seven Deadly Sins: Origin open-world expansion

The real reason Netmarble is launching The Seven Deadly Sins: Origin in phases

Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data

Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit

Representative image showing the intersection of financial performance and cancer diagnostics, reflecting Exact Sciences’ record 2025 results and its pending acquisition by Abbott Laboratories.

Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition

Dave & Buster’s lands in the Philippines with Opus Mall launch — more Asia-Pacific openings coming

Dave & Buster’s debuts in the Philippines with its first location at Opus Mall, signaling a broader Asia-Pacific expansion push. Find out what’s next.

bySrinath

October 17, 2025

Dave & Buster’s targets $675m EBITDA and 11 new stores — will its turnaround plan satisfy Wall Street?

Dave & Buster’s (NASDAQ: PLAY) targets $675M EBITDA and 11 new stores in 2025. Can its strategy reset revive same-store sales and investor sentiment?

byPallavi Madhiraju

September 16, 2025

The Latest

The real reason Netmarble is launching The Seven Deadly Sins: Origin in phases

Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data

Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit

Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition

Dave & Buster’s lands in the Philippines with Opus Mall launch — more Asia-Pacific openings coming

Dave & Buster’s targets $675m EBITDA and 11 new stores — will its turnaround plan satisfy Wall Street?

The real reason Netmarble is launching The Seven Deadly Sins: Origin in phases

Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data

Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit

Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition

Bank of America boosts Brian Moynihan’s 2025 pay to $41m amid governance scrutiny

X-energy advances SMR commercialization with TRISO-X HALEU license and long-term graphite supply deal

FDA Complete Response Letter puts Disc Medicine Inc.’s bitopertin timeline under pressure